Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized comparison of double unrelated umbilical cord blood versus haploidentical related bone marrow transplantation after reduced-intensity conditioning
2013-004526-28Phase 3Terminated
- Sponsor
- National Institutes of Health
- Start
- Mar 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hematopoietic stem cells in hematopoietic malignancies, lymphoma and Hodgkin lymphoma (HL) (2 arms), sponsored by National Institutes of Health. Primary endpoint: Progression-free survival. Started Mar 2014; status: terminated.
02
Drugs
hematopoietic stem cells
03
Conditions
hematopoietic malignancieslymphomaHodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2013-004526-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004526-28.